Quotient Clinical, a provider of early stage and specialized drug development services, has signed an agreement with Nuformix Technologies to evaluate Nuformix’ lead pharmaceutical cocrystal, NXP001, using translational pharmaceutics in the field of oncology. Quotient will use its Translational Pharmaceutics platform to develop a formulated oral NXP001 cocrystal product and validate its performance in healthy subjects.   Pharmaceutical cocrystals are re-engineered crystalline forms of small mo...